Get the Stockscreener App
6.10
3.39%
0.20
After Hours:
6.27
0.17
+2.79%
Personalis Inc stock is traded at $6.10, with a volume of 2.44M.
It is up +3.39% in the last 24 hours and down -21.59% over the past month.
Personalis Inc is a provider of genomic sequencing and analytics solutions to support the development of personalized cancer vaccines and other next-generation cancer immunotherapies. It has one segment, the sale of sequencing and data analysis services. The company' products include ImmunoID NeXT, NeXT Personal, NeXT Dx Test, and other pharma research solutions.
See More
Previous Close:
$5.90
Open:
$5.9
24h Volume:
2.44M
Relative Volume:
1.61
Market Cap:
$638.54M
Revenue:
$69.65M
Net Income/Loss:
$-81.27M
P/E Ratio:
-6.7121
EPS:
-0.9088
Net Cash Flow:
$-79.45M
1W Performance:
-9.36%
1M Performance:
-21.59%
6M Performance:
-36.98%
1Y Performance:
+59.27%
1-Day Range:
$5.86
$6.18
1-Week Range:
$5.688
$6.603
52-Week Range:
$3.62
$11.50
Personalis Inc Stock (PSNL) Company Profile
Name
Personalis Inc
Sector
Industry
Phone
650-752-1300
Address
6600 DUMBARTON CIRCLE, FREMONT, CA
Compare PSNL vs TMO, DHR, IDXX, A, WAT
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
PSNL
Personalis Inc
|
6.10 | 617.60M | 69.65M | -81.27M | -79.45M | -0.9088 |
TMO
Thermo Fisher Scientific Inc
|
469.71 | 173.44B | 45.20B | 6.88B | 6.75B | 18.19 |
DHR
Danaher Corp
|
177.25 | 126.39B | 24.78B | 3.68B | 5.29B | 5.1743 |
IDXX
Idexx Laboratories Inc
|
565.93 | 44.55B | 4.30B | 1.06B | 1.04B | 13.08 |
A
Agilent Technologies Inc
|
115.55 | 32.34B | 7.07B | 1.29B | 993.00M | 4.5355 |
WAT
Waters Corp
|
309.87 | 30.55B | 3.17B | 642.63M | 516.49M | 10.77 |
Personalis Inc Stock (PSNL) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-02-25 | Resumed | Morgan Stanley | Equal-Weight |
| May-15-25 | Initiated | Guggenheim | Buy |
| Mar-17-25 | Initiated | Craig Hallum | Buy |
| Feb-06-23 | Upgrade | Needham | Hold → Buy |
| Jan-07-22 | Upgrade | BofA Securities | Neutral → Buy |
| Nov-05-21 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Nov-03-21 | Downgrade | Needham | Buy → Hold |
| Oct-15-21 | Resumed | Cowen | Outperform |
| Sep-20-21 | Reiterated | Needham | Buy |
| May-06-21 | Upgrade | Oppenheimer | Perform → Outperform |
| Jan-28-21 | Initiated | Truist | Buy |
| Jan-04-21 | Downgrade | BofA Securities | Buy → Neutral |
| Nov-12-20 | Reiterated | Needham | Buy |
| Nov-06-20 | Downgrade | Oppenheimer | Outperform → Perform |
| Oct-19-20 | Initiated | Citigroup | Buy |
| Oct-08-20 | Initiated | BTIG Research | Buy |
| Aug-27-20 | Initiated | H.C. Wainwright | Buy |
| Aug-18-20 | Initiated | Needham | Buy |
| Sep-26-19 | Upgrade | BofA/Merrill | Neutral → Buy |
| Jul-15-19 | Initiated | BofA/Merrill | Neutral |
| Jul-15-19 | Initiated | Cowen | Outperform |
| Jul-15-19 | Initiated | Morgan Stanley | Overweight |
| Jul-15-19 | Initiated | Oppenheimer | Outperform |
View All
Personalis Inc Stock (PSNL) Latest News
Personalis to Announce First Quarter 2026 Financial Results - Business Wire
Multiple Insiders Sold Personalis Shares Presenting Weak Signs For Investors - 富途牛牛
Personalis Highlights Clinical Impact of Ultrasensitive ctDNA Monitoring and New Therapy Resistance Tracking at AACR 2026 - BioSpace
InvestingPro’s Fair Value predicted 40% drop in Personalis stock By Investing.com - Investing.com
Personalis presents ctDNA monitoring data at cancer research meeting - Investing.com
Needham Maintains Personalis(PSNL.US) With Buy Rating, Maintains Target Price $12 - Moomoo
Personalis (NASDAQ:PSNL) Shares Up 6.8%What's Next? - MarketBeat
Personalis and Collaborators to Highlight Ultrasensitive ctDNA Data and New Therapy Resistance Tracking Capabilities at AACR 2026 - BioSpace
Earnings Beat: Can Personalis Inc deliver consistent EPS growth2026 Pullbacks & Technical Pattern Alert System - baoquankhu1.vn
Breakouts Watch: What is Personalis Incs revenue forecastPortfolio Update Summary & High Accuracy Trade Signal Alerts - baoquankhu1.vn
Form 4Statement of changes in beneficial ownership of securities - ADVFN
Trade Recap: Is Personalis Inc benefiting from interest rate changesWeekly Gains Summary & Entry Point Strategy Guides - baoquankhu1.vn
T. Rowe Price lists 4.5% stake in Personalalis (NASDAQ: PSNL) - Stock Titan
Can Personalis Inc stock double in the next yearMarket Weekly Review & Weekly Top Gainers Trade List - baoquankhu1.vn
Market Rankings: Can Personalis Inc stock double in the next yearTrade Performance Summary & Daily Price Action Insights - baoquankhu1.vn
Personalis, Inc. $PSNL Shares Acquired by Aberdeen Group plc - MarketBeat
Is Personalis (PSNL) Stock Risky Now | Price at $6.61, Up 0.46%Shared Momentum Picks - Xã Châu Thành
Personalis, Inc. (NASDAQ:PSNL) Receives Consensus Recommendation of "Moderate Buy" from Analysts - MarketBeat
Whale Trades: Whats the beta of Personalis Inc stock2026 Market Sentiment & Weekly High Momentum Picks - baoquankhu1.vn
PSNL Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
PSNL Stock News Today | Earnings, Events & Price Alerts - Intellectia AI
PSNL Stock Analysis: Personalis Inc. Modest Daily Uptick At 6.58 USD Amid Genomics Sector Trends - Cổng thông tin điện tử tỉnh Lào Cai
Executive pay, board elections headline Personalis (PSNL) 2026 proxy - Stock Titan
Personalis, Inc. (PSNL) stock price, news, quote and history - Yahoo Finance Singapore
Personalis to Participate in the 25th Annual Needham Virtual Conference - ChartMill
PSNL Stock Analysis: Personalis Inc. gains 4.24 pct, holds 6.64 dollar level - Cổng thông tin điện tử tỉnh Tây Ninh
Operating cash flow per share of Personalis, Inc. – DUS:04X - TradingView
Personalis Surges 12% Pre-Market with No Clear Catalyst - Bitget
Morgan Stanley lowers Personalis (PSNL) price target to $10 - MSN
Dow Update: Is Personalis Inc benefiting from interest rate changesMarket Volume Report & Free Weekly Watchlist of Top Performers - baoquankhu1.vn
Personalis (NASDAQ:PSNL) Trading Down 9.3%Should You Sell? - MarketBeat
Personalis stock rises after Medicare approves lung cancer test coverage - Investing.com
Sell Signal: Can Personalis Inc deliver consistent EPS growthOil Prices & Weekly Setup with High ROI Potential - baoquankhu1.vn
Morgan Stanley Lowers Personalis (PSNL) Price Target to $10 - Insider Monkey
10 best diagnostics and research stocks to buy according to analysts - msn.com
Should you avoid Personalis Inc stock right now2026 Trade Ideas & Weekly Breakout Opportunity Watchlist - baoquankhu1.vn
PSNL SEC FilingsPersonalis 10-K, 10-Q, 8-K Forms - Stock Titan
Personalis, Inc. (PSNL): A bull case theory - MSN
Personalis appoints Richard Chen as president and updates compensation package - au.investing.com
229,435 Shares in Personalis, Inc. $PSNL Bought by Oracle Investment Management Inc. - MarketBeat
Personalis Appoints Dr. Richard Chen as President to Further Accelerate MRD Adoption - BioSpace
Personalis promotes Richard Chen to president role By Investing.com - Investing.com South Africa
Personalis appoints Richard Chen as president and updates compensation package By Investing.com - Investing.com India
Personalis (PSNL) Appoints Richard Chen as President - GuruFocus
Personalis (PSNL) CFO granted 206,250 options and 34,375 RSUs - Stock Titan
Personalis (PSNL) grants options and RSUs to Chief Legal Officer - Stock Titan
Personalis (PSNL) CEO receives major stock option and RSU grants - Stock Titan
Personalis (PSNL) awards RSUs and stock options to its CMO - Stock Titan
Investor Mood: Can Personalis Inc grow without external funding2026 Chart Watch & Expert Approved Trade Ideas - baoquankhu1.vn
Personalis promotes Richard Chen to president role - Investing.com
Personalis (NASDAQ: PSNL) elevates Richard Chen to President - Stock Titan
Personalis Inc Stock (PSNL) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.42%
1.43%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):